Methods of treating tki-resistant and sdh-deficient gist

A method of identifying a subject having a disease, disorder or condition associated with SDH-deficiency and selecting a treatment for the identified subject, comprising:

• a) determining if a biological sample from the subject is SDH-deficient;
• b) identifying the subject as having the disease, disorder or condition associated with SDH-deficiency, based on the SDH-deficiency determined in step a), and
• c) recommending the subject to receive treatment of a multi-targeted TKI.

A method of treating cancer in a subject, comprising administering to the subject,

• a) a therapeutically effective amount of a multi-targeted tyrosine kinase inhibitor (TKI);
• and
• b) a therapeutically effective amount of a Bcl-2 inhibitor.

A method of treating a disease, disorder or condition associated with upregulated hypoxia inducible factors (HIF-1α, HIF-2α), vascular endothelial growth factor-A (VEGFA), fibroblast growth factor receptor-1 (FGFR1), phosphorylated FGFR1, insulin-like growth factor-1 receptor (IGF-1R), phosphorylated IGF-1R, STAT3, phosphorylated STAT3 and/or phosphorylated Src in a subject, comprising administering a therapeutically effective amount of a multi-targeted tyrosine kinase inhibitor (TKI) to the subject, thereby treating the disease, disorder or condition associated with lipid metabolism in the subject.